相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA)
Natalie N. Kinloch et al.
NATURE COMMUNICATIONS (2021)
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial
Sarah Fidler et al.
LANCET (2020)
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
Julia Niessl et al.
NATURE MEDICINE (2020)
BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo
Yanqin Ren et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial
Miriam Posas-Umbert et al.
FRONTIERS IN IMMUNOLOGY (2020)
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
Beatriz Mothe et al.
FRONTIERS IN IMMUNOLOGY (2020)
A quantitative approach for measuring the reservoir of latent HIV-1 proviruses
Katherine M. Bruner et al.
NATURE (2019)
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting
Boris Julg et al.
LANCET HIV (2019)
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Marina Caskey et al.
NATURE MEDICINE (2019)
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
Yehuda Z. Cohen et al.
PLOS ONE (2019)
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV plus individuals
Carolina Garrido et al.
AIDS (2019)
TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy
So-Yon Lim et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies
Golnaz Namazi et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Pilar Mendoza et al.
NATURE (2018)
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys
Erica N. Borducchi et al.
NATURE (2018)
Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs
G. Tapia et al.
JOURNAL OF INFECTION (2017)
Early antibody therapy can induce long-lasting immunity to SHIV
Yoshiaki Nishimura et al.
NATURE (2017)
The potential role for romidepsin as a component in early HIV-1 curative efforts
Jesper Damsgaard Gunst et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2016)
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid et al.
NATURE (2016)
Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo
Ching-Lan Lu et al.
SCIENCE (2016)
Combined eff ect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
Steffen Leth et al.
LANCET HIV (2016)
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey et al.
NATURE (2015)
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S. Sogaard et al.
PLOS PATHOGENS (2015)
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
Julian H. Elliott et al.
LANCET HIV (2015)
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Stylianos Bournazos et al.
CELL (2014)
Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice
Ariel Halper-Stromberg et al.
CELL (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen et al.
LANCET HIV (2014)
Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
Liang Shan et al.
IMMUNITY (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
TRIALS (2010)
分享论文
